Biotech Pops On New Patient Enrollment Announcement

Biotech Pops On New Patient Enrollment Announcement

By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, November 30, 2022

A California-based biotech company turned heads on Wednesday after the company announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in cystic fibrosis (CF) patients. According to the release, the company is on track to complete database lock, data analyses, and disclose top-line data in the first quarter of 2023.

This sent shares of Aridis Pharmaceuticals Inc. (Nasdaq:ARDS) up to $0.9833/share (+9.26%) at the early session high. Keep you eyes on this one for sessions to come!

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Shares on the Rise Following Partnership News With Major Potato Chip Brand
Slowing Growth Increases Hopes of a Rate Cut Pivot in Canada 
Re-Classification of Marijuana Sends Shares of Cannabis Operator on a Tear
Most Popular
FREE Newsletter


Back to Top